Type II Diabetes: The 45+ Market in the United States for Drugs and Diagnostics : Kalorama Information

Type II Diabetes: The 45+ Market in the United States for Drugs and Diagnostics

Jan 1, 2004
303 Pages - Pub ID: KLI910424

Ask a question about this report

Email a colleague

Printer format

Order by fax

Abstract

Table of Contents

Search Inside Report

Buy By the Section

Related Reports

Type II diabetes is a metabolic disease the increases in incidence and prevalence with age. Type II diabetes (also known as "adult onset diabetes" and "non-insulin dependent diabetes") is a disease of glucose metabolism in which the individual becomes resistant to the glucose produced by the pancreas. As a result, glucose is not properly metabolized and serum glucose levels are increased, resulting in numerous complications vascular, renal, neurological and ophthalmological complications as the patient ages.

This volume of the Markets in Geriatric Medicine Series will look at the mechanisms involved in the pathology of both Type II diabetes, and the specific molecular processes that define this disease. The report will look at the technology and markets available for monitoring glucose levels, by patients, and the assays for hemoglobin A1C, ketones and microalbumin that are used to follow the progress of the disease and its complications.

It will also explore current treatment modalities for Type II diabetes, including oral hypoglycemics and insulin. It will describe new and emerging research and development efforts into the discovery of new therapeutic products that address this disease such as new oral hypoglycemic agents and both oral and inhaled dosage forms of insulin. We will investigate and discuss the latest in progress towards clinical development of biopharmaceuticals and cell-based therapeutics that may be introduced over the next decade for the treatment of Type II diabetes at its most basic level.

The report will look at the demographics of the aging United States population, the expected incidence and prevalence of Type II diabetes, and the United States markets for monitoring products and therapeutics, currently estimated at $4.5 billion and $5.5 billion, respectively, that are expected grow around these populations.

Related Reports: